

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Imai N, Ikeda K, Seko Y, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Saitoh S, <u>Suzuki F</u> , Suzuki Y, Arase Y, Kumada H.	Previous chemoembolization response after transcatheter arterial chemoembolization (TACE) can predict the anti-tumor effect of subsequent TACE with miriplatin in patients with recurrent hepatocellular carcinoma.	Oncology	80 (3-4)	188-94	2011
Arase Y, <u>Suzuki F</u> , Kobayashi M, Suzuki Y, Kawamura Y, Matsumoto N, Akuta N, Kobayashi M, Sezaki H, Saito S, Hosaka T, Ikeda K, Kumada H, Ohmoto Y, Amakawa K, Tsuji H, Hsieh SD, Kato K, Tanabe M, Ogawa K, Hara S, Kobayashi T.	The development of chronic kidney disease in Japanese patients with non-alcoholic fatty liver disease.	Intern Med.	50 (10)	1081-7	2011
Akuta N, <u>Suzuki F</u> , Hirakawa M, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H.	Amino acid substitutions in hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by antiviral therapy.	J Med Virol	83(6)	1016-22	2011
Ikeda K, Kobayashi M, Kawamura Y, Imai N, Seko Y, Hirakawa M, Hosaka T, Sezaki H, Akuta N, Saitoh S, <u>Suzuki F</u> , Suzuki Y, Arase Y, Kumada H.	Stage progression of small hepatocellular carcinoma after radical therapy: comparisons of radiofrequency ablation and surgery using the Markov model.	Liver Int.	31(5)	692-9	2011
Arase Y, <u>Suzuki F</u> , Kobayashi M, Suzuki Y, Kawamura Y, Matsumoto N, Akuta N, Imai N, Kobayashi M, Sezaki H, Saito S, Hosaka T, Ikeda K, Kumada H, Ohmoto Y, Amakawa K, Tsuji H, Hsieh SD, Kobayashi T.	Efficacy and safety in sitagliptin therapy for diabetes complicated by chronic liver disease caused by hepatitis C virus.	Hepatol Res.	41(6)	524-9	2011

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Ozeki I, Akaike J, Karino Y, Arakawa T, Kuwata Y, Ohmura T, Sato T, Kamiya N, Yamada I, Chayama K, Kumada H, Toyota J.	Antiviral effects of peginterferon alpha-2b and ribavirin following 24-week monotherapy of telaprevir in Japanese hepatitis C patients.	J Gastroenterol	46(7)	929-37	2011
Azakami T, Hayes CN, Sezaki H, Kobayashi M, Akuta N, <u>Suzuki F</u> , Kumada H, Abe H, Miki D, Tsuge M, Imamura M, Kawakami Y, Takahashi S, Ochi H, Nakamura Y, Kamatani N, Chayama K.	Common genetic polymorphism of ITPA gene affects ribavirin-induced anemia and effect of peg-interferon plus ribavirin therapy.	J Med Virol	83(6)	1048-57	2011
Yamada I, <u>Suzuki F</u> , Kamiya N, Aoki K, Sakurai Y, Kanou M, Matsui H, Kumada H.	Safety, pharmacokinetics, and resistant variants of telaprevir for 12 weeks in hepatitis C virus genotype 1b infection.	J Viral Hepat Jul	Epub ahead of print	112-119	2012
Akuta N, <u>Suzuki F</u> , Hirakawa M, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Chayama K, Nakamura Y, Kumada H.	Amino acid substitution in HCV core/NS5A region and genetic variation near IL28B gene affect treatment efficacy to interferon plus ribavirin combination therapy.	Intervirology	Epub ahead of print		2011
Akuta N, <u>Suzuki F</u> , Hirakawa M, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Chayama K, Nakamura Y, Kumada H.	Amino acid substitution in HCV core region and genetic variation near the IL28B gene affect viral dynamics during telaprevir, peginterferon and ribavirin treatment.	Intervirology	Epub ahead of print		2011
Kawamura Y, Arase Y, Ikeda K, Seko Y, Imai N, Hosaka T, Kobayashi M, Saitoh S, Sezaki H, Akuta N, <u>Suzuki F</u> , Suzuki Y, Ohmoto Y, Amakawa K, Tsuji H, Kumada H.	Large-Scale Long-Term Follow-Up Study of Japanese Patients With Non-Alcoholic Fatty Liver Disease for the Onset of Hepatocellular Carcinoma.	Am J Gastroenterol	Epub ahead of print		2011

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
鈴木義之、瀬崎ひとみ、芥田憲夫、鈴木文孝、今井則博、平川美晴、川村祐介、保坂哲也、小林正宏、斎藤聡、荒瀬康司、池田健次、小林万利子、熊田博光	NS5A阻害剤とNS3プロテアーゼ阻害剤併用投与における早期抗ウイルス効果	肝臓	52(2)	147-9	2011
保坂哲也、鈴木文孝、小林正宏、瀬古裕也、今井則博、平川美晴、川村祐介、瀬崎ひとみ、芥田憲夫、鈴木義之、斎藤聡、荒瀬康司、池田健次、小林万利子、熊田博光	B型慢性肝疾患に対する核酸アナログ療法によるHBs抗原消失とその関連因子の検討	肝臓	52(4)	255-7	2011
小林万利子、鈴木文孝、鈴木義之、芥田憲夫、瀬崎ひとみ、川村祐介、瀬古裕也、保坂哲也、小林正宏、斎藤聡、荒瀬康司、池田健次、熊田博光	コバスTaqManHBV「オート」v2.0における同一時の血清検体と血漿検体のHBVDNA検出率の検討	肝臓	52(11)	756-7	2011
小関 至、狩野吉康、豊田成司、高橋祥一、川上由育、茶山一彰、芥田憲夫、鈴木文孝、熊田博光	PEG-IFN/Ribavirin/Telaprevir三剤併用療法における薬剤投与率の抗ウイルス効果に及ぼす影響	肝臓		69-77	2012
<u>Kanto, T.</u> , Inoue, M., Oze, T., Miyazaki, M., Sakakibara, M., Kakita, N., Matsubara, T., Higashitani, K., Hagiwara, H., Iio, S., Katayama, K., Mita, E., Kasahara, A., Hiramatsu, N., Takehara, T. and Hayashi, N.	Dynamics of regulatory T cells and plasmacytoid dendritic cells as immune markers for virological response in pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C patients.	J Gastroenterol	47	169-178	2011
Tatsumi, T., Takehara, T., Miyagi, T., Nakazuru, S., Mita, E., <u>Kanto, T.</u> , Hiramatsu, N. and Hayashi, N.	Hepatitis C virus-specific CD8+ T cell frequencies are associated with the responses of pegylated interferon-alpha and ribavirin combination therapy in patients with chronic hepatitis C virus infection.	Hepatol Res	41	30-38	2011

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Miyagi, T., Shimizu, S., Tatsumi, T., Nishio, K., Hiramatsu, N., <u>Kanto, T.</u> , Hayashi, N. and Takehara, T.,	Differential alteration of CD56(bright) and CD56 (dim) natural killer cells in frequency, phenotype, and cytokine response in chronic hepatitis C virus infection.	J Gastroenterol	46	1020-1030	2011
Ishida, H., Tatsumi, T., Hosui, A., Nawa, T., Kodama, T., Shimizu, S., Hikita, H., Hiramatsu, N., <u>Kanto, T.</u> , Hayashi, N. and Takehara, T.	Alterations in microRNA expression profile in HCV- infected hepatoma cells: involvement of miR-491 in regulation of HCV replication via the PI3 kinase/Akt pathway.	Biochem Biophys Res Commun	412	92-97	2011
Itakura J, <u>Asahina Y</u> , Tamaki N, Hirayama I, Yasui Y, Tanaka T, Sato M, Ueda K, Kuzuya T, Tsuchiya K, Nakanishi H, Kurosaki M, Gabriel GS, Schneider, Izumi N.	Changes in hepatitis C viral load during first 14 days can predict the undetectable time point of serum viral load by pegylated interferon and ribavirin therapy.	Heptol Res	In press		2011
<u>Yasuhiro Asahina</u> , Kaoru Tsuchiya, Masaru Muraoka, Keisuke Tanaka, Yuichiro Suzuki, Nobuharu Tamaki, Yoshihide Hoshioka, Yutaka Yasui, Tomoji Katoh, Takanori Hosokawa, Ken Ueda, Hiroyuki Nakanishi, Jun Itakura, Yuka Takahashi, Masayuki Kurosaki, Nobuyuki Enomoto, Sayuri Nitta, Naoya Sakamoto, Namiki Izumi.	Association of gene expression involving innate immunity and genetic variation in IL28B with antiviral response	Hepatology	2012 ; 55	20-29	2011
Masayuki Kurosaki, <u>Yasuhiro Asahina</u> , Namiki Izumi, et., al.	Pre-treatment prediction of response to pegylated- interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors	Journal of Hepatology	54	439-448	2011

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
<u>Yasuhiro Asahina</u> , Namiki Izumi, et., al.	Characterization of naturally occurring protease inhibitor-resistance mutations in genotype 1b hepatitis C virus patients	Hepatology International	On line		2011
Kaoru Tsuchiya, Mina Komuta, Yutaka Yasui, Nobuharu Tamaki, Takanori Hosokawa, Ken Ueda, Teiji Kuzuya, Jun Itakura, Hiroyuki Nakanishi, Yuka Takahashi, Masayuki Kurosaki, <u>Yasuihiro Asahina</u> , Nobuyuki Enomoto, Michiie Sakamoto, Namiki Izumi	Expression of Keratin 19 Is Related to High Recurrence of Hepatocellular Carcinoma after Radiofrequency Ablation	Oncology	80	278-288	2011
Teiji Kuzuya, <u>Yasuhiro Asahina</u> , Kaoru Tsuchiya, Keisuke Tanaka, Yuichiro Suzuki, Takahide Hoshioka, Shinji Tamaki, Tomoji Kato, Yutaka Yasui, Takahiro Hosokawa, Ken Ueda., Hiroyuki Nakanishi, Jun Itakura, Yuka Takahashi, Masayuki Kurosaki, Namiki Izumi	Early Decrease in $\alpha$ -Fetoprotein, but Not Des- $\gamma$ -Carboxy Prothrombin, Predicts Sorafenib Efficacy in Patients with Advanced Hepatocellular Carcinoma	Oncology	81	251-258	2011
Fujinaga H, Tsutsumi T, Yotsuyanagi H, <u>Moriya K</u> , Koike K	Hepatocarcinogenesis in hepatitis C: HCV shrewdly exacerbates oxidative stress by modulating both production and scavenging of reactive oxygen species	Oncology	81	11-17	2011
Nukui Y, Hatakeyama S, Kitazawa T, Mahira T, Shintani Y, <u>Moriya K</u>	Pandemic 2009 influenza A(H1N1) virus among Japanese healthcare workers: seroprevalence and risk factors	Infection control and hospital epidemiology	33	58-62	2012

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Kurano M, Isoo N, Hara M, Ishizaka N, <u>Moriya K</u> , Koike K, Tsukamoto K	LXR agonist increases apoE secretion from hepG2 spheroid, together with an increased production of VLDL and apoE-rich large HDL	Lipids in health and disease	10	134-143	2011
Koshiyama A, Ichibangase T, <u>Moriya K</u> , Koike K, Yazawa I, Imai K	Liquid chromatographic separation of proteins derivatized with a fluorogenic reagent at cysteinyl residues on a non-porous for differential proteomics analysis	Journal of chromatography A	1218	3447-3452	2011
Miyoshi H, <u>Moriya K</u> , Tsutsumi T, Shinzawa S, Fujie H, Shintani Y, Fujinaga H, Goto K, Todoroki T, Suzuki T, Miyamura T, Matsuura Y, Yotsuyanagi H, Koike K	Pathogenesis of lipid metabolism disorder in hepatitis C: polyunsaturated fatty acids counteract alterations induced by the core protein	Journal of hepatology	54	432-438	2011
Nagai R, Saito R, Koyano S, Okamura N, Yokota H, Kitazawa T, <u>Moriya K</u>	Evaluation of multiplex PCR using dual-priming	Clin chem. Lab med	49	751-752	2011
Kurosaki M, Hiramatsu N, <u>Sakamoto M</u> , Suzuki Y, Iwasaki M, Tamori A, Matsuura K, Sugauchi F, Sakamoto N, Yatsuhashi H, Izumi N	Age and total ribavirin dose are independent predictors of relapse after interferon therapy in chronic hepatitis C revealed by data mining analysis.	Antiviral Therapy	17	35-43	2012
Kurosaki M, Hiramatsu N, <u>Sakamoto M</u> , Suzuki Y, Iwasaki M, Tamori A, Matsuura K, Kakinuma S, Sugauchi F, Sakamoto N, Nakagawa M, Izumi N	Data mining model using simple and readily available factors could identify patients at high risk for hepatocellular carcinoma in chronic hepatitis C.	J Hepatol	In press		2012
Osada M, Kaneko M, <u>Sakamoto M</u> , Endoh M, Takigawa K, Inoue-Suzuki K, Inoue O, Satoh K, Enomoto N, Yatomi Y, Ozaki Y	Causes of thrombocytopenia in chronic hepatitis C viral infection.	Clinical and Applied Thrombosis/Hemostasis	In press		2012

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Shindo H, Maekawa S, Komase K, Sueki R, Miura M, Kadokura M, Shindo K, Amemiya F, Kitamura T, Nakayama Y, Inoue T, <u>Sakamoto M</u> , Okada S, Asahina Y, Izumi N, Honda M, Kaneko S, Enomoto N.	Characterization of naturally occurring protease inhibitor-resistance mutations in genotype 1b hepatitis C virus patients.	Hepatol Int	Online First™, 18 August		2011
Miura M, Maekawa S, Kadokura M, Sueki R, Komase K, Shindo H, Ohmori T, Kanayama A, Shindo K, Amemiya F, Nakayama Y, Kitamura T, Uetake T, Inoue T, <u>Sakamoto M</u> , Okada S, Enomoto N	Analysis of viral amino acids sequences and the IL28B SNP influencing the development of hepatocellular carcinoma in chronic hepatitis C.	Hepatol Int	Hepatol Int; Online First™, 17 August		2011
Kadokura M, Maekawa S, Sueki R, Miura M, Komase K, Shindo H, Amemiya F, Uetake T, Inoue T, <u>Sakamoto M</u> , Nakagawa M, Sakamoto N, Watanabe M, Enomoto N.	Analysis of the complete open reading frame of genotype 2b hepatitis C virus in association with the response to peginterferon and ribavirin therapy.	Plos One	6(9)	e24514	2011
Hiramatsu N, Kurosaki M, Sakamoto N, Iwasaki M, <u>Sakamoto M</u> , Suzuki Y, Sugauchi F, Tamori A, Matsuura K, Izumi N.	Pretreatment prediction of anemia progression by pegylated interferon alpha-2b plus ribavirin combination therapy in chronic hepatitis C infection: Decision-tree analysis.	J Gastroenterol	46	1111-1119	2011
Kurosaki M, Tanaka Y, Nishida N, Sakamoto N, Enomoto N, Honda M, Sugauchi M, Matsuura K, Sugauchi F, Asahina Y, Nakagawa M, Watanabe M, <u>Sakamoto M</u> , Maekawa S, Sakai A, Kaneko S, Ito K, Masaki N, Tokunaga K, Izumi N, Mizokami M.	Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors.	J Hepatol	54	439-448	2011

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Kadokura M, Maekawa S, Sueki R, Miura M, Komase K, Shindo H, Amemiya F, Uetake T, Inoue T, <u>Sakamoto M</u> , Nakagawa M, Sakamoto N, Watanabe M, Enomoto N	Analysis of the complete open reading frame of hepatitis C virus genotype 2a infection reveals critical site influencing the response to peginterferon and ribavirin therapy.	Hepatol Int	5(3)	789-799	2011
Kurosaki M, Sakamoto N, Iwasaki M, <u>Sakamoto M</u> , Suzuki Y, Hiramatsu N, Sugauchi F, Tamori A, Nakagawa M, Izumi N	Sequences in the Interferin Sensitivity Determining Region and Core Region of Hepatitis C Virus Impact Pretreatment Prediction of Response to Peg-interferon Plus Ribavirin: Data Mining Analysis.	J Med Virol	83	445-452	2011
Kurosaki M, Sakamoto N, Iwasaki M, <u>Sakamoto M</u> , Suzuki Y, Hiramatsu N, Sugauchi F, Yatsushashi H, Izumi N.	Pretreatment prediction of response to peginterferon plus ribavirin therapy in genotype 1 chronic hepatitis C using data mining analysis.	J Gastroenterol	46	401-409,	2011
Honda M, Takehana K, <u>Sakai A</u> , Tagata Y, Shirasaki T, Nishitani S, Muramatsu T, Yamashita T, Nakamoto Y, Mizukoshi E, Sakai Y, Yamashita T, Nakamura M, Shimakami T, Yi M, Lemon SM, Suzuki T, Wakita T, Kaneko S; Hokuriku Liver Study Group	Malnutrition impairs interferon signaling through mTOR and FoxO pathways in patients with chronic hepatitis C	Gastroenterology	141	128-140	2011
Nagatsu A, <u>Taniguchi M</u> , Shimamura T, Suzuki T, Yamashita K, Kawakami H, Abo D, Kamiyama T, Furukawa H, Todo S.	Endoscopic naso-pancreatic drainage for the treatment of pancreatic fistula occurring after LDLT.	World J Gastroenterol.	17 (30)	3560-4	2011
Joshita S, <u>Umemura T</u> , Katsuyama Y, Ichikawa Y, Kimura T, Morita S, Kamiyo A, Komatsu M, Ichijo T, Matsumoto A, Yoshizawa K, Kamiyo N, Ota M, Tanaka E.	Association of IL28B gene polymorphism with development of hepatocellular carcinoma in Japanese patients with chronic hepatitis C virus infection.	Hum Immunol	Epub ahead of print		2012



発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Yoneda S, <u>Umemura T</u> , Joshita S, Ichijo T, Matsumoto A, Yoshizawa K, Katsuyama Y, Ota M, Tanaka E.	Serum chemokine levels are associated with the outcome of pegylated interferon and ribavirin therapy in patients with chronic hepatitis C.	Hepatol Res	41	587-93	2011
<u>Umemura T</u> , Joshita S, Yoneda S, Katsuyama Y, Ichijo T, Matsumoto A, Yoshizawa K, Ota M, Tanaka E.	Serum IL-10 and IL-12p40 levels and IL28B gene polymorphisms: pretreatment prediction of treatment failure in chronic hepatitis C.	Antivir Ther	16	1073-80	2011
Yoneda S, <u>Umemura T</u> , Katsuyama Y, Kamijo A, Joshita S, Komatsu M, Ichijo T, Matsumoto A, Yoshizawa K, Ota M, Tanaka E.	Association of serum cytokine levels with treatment response to pegylated interferon and ribavirin therapy in genotype 1 chronic hepatitis C patients.	J Infect Dis	203	1087-1095	2011
<u>Sainz B Jr</u> , <u>Barretto N</u> , <u>Martin DN</u> , <u>Hiraga N</u> , <u>Imamura M</u> , <u>Hussain S</u> , <u>Marsh KA</u> , <u>Yu X</u> , <u>Chayama K</u> , <u>Alrefai WA</u> , <u>Uprichard SL</u> .	Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor.	Nat Med	18(2)	281-5	2012
Akuta N, <u>Suzuki F</u> , Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H.	Amino acid substitutions in the hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to Telaprevir with peginterferon and ribavirin	Hepatology	52 (2)	421-429	2010
Kobayashi M, Akuta N, <u>Suzuki F</u> , Hosaka T, Sezaki H, Kobayashi M, Suzuki Y, Arase Y, Ikeda K, Watahiki S, Mineta R, Iwasaki S, Miyakawa Y, Kumada H.	Influence of amino-acid polymorphism in the core protein on progression of liver disease in patients infected with hepatitis C virus genotype 1b.	J Med Virol	82	41-48	2010

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
<u>Suzuki F</u> , Suzuki Y, Akuta N, Sezaki H, Yatsuji H, Arase Y, Hirakawa M, Kawamura Y, Hosaka T, Kobayashi M, Saitoh S, Ikeda K, Kobayashi M, Watahiki S, Mineta R, Iwasaki S, Kumada H.	Sustained virological response in a patient with chronic hepatitis C treated by monotherapy with the NS3-4A protease inhibitor telaprevir.	J cln virol	47 (1)	76-78	2010
Arase Y, <u>Suzuki F</u> , Suzuki Y, Akuta N, Kobayashi M, Sezaki H, Hosaka T, Kawamura Y, Yatsuji H, Hirakawa M, Ikeda K, Kobayashi M, Kumada H.	Virus clearance reduces bone fracture in postmenopausal women with osteoporosis and chronic liver disease caused by hepatitis C virus.	J Med Virol	82	390-395	2010
Kobayashi M, <u>Suzuki F</u> , Akuta N, Yatsuji H, Hosaka T, Sezaki H, Kobayashi M, Kobayashi M, Kawamura Y, Suzuki Y, Arase Y, Ikeda K, Mineta R, Iwasaki S, Watahiki S, Kumada H.	Correlation of YMDD mutation and breakthrough hepatitis with hepatitis B virus DNA and serum ALT during lamivudine treatment.	Hepatol Res	40 (2)	125-134	2010
Hosaka T, <u>Suzuki F</u> , Kobayashi M, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Akuta N, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Miyakawa Y, Kumada H.	Development of HCC in patients receiving adefovir dipivoxil for lamivudine-resistant hepatitis B virus mutants.	Hepatol Res	40 (2)	145-152	2010
Kumada H, Okanoue T, Onji M, Moriwaki H, Izumi N, Tanaka E, Cyayama K, Sakisaka S, Takehara T, Oketani M, <u>Suzuki F</u> , Toyota J, Nomura H, Yoshioka K, Seike M, Yotsuyanagi H, Ueno Y.	Guidelines for the treatment of chronic hepatitis and cirrhosis induced by hepatitis B virus infection for the fiscal year 2008 in Japan.	Hepatol Res	40 (1)	1-7	2010
Kumada H, Okanoue T, Onji M, Moriwaki H, Izumi N, Tanaka E, Cyayama K, Sakisaka S, Takehara T, Oketani M, <u>Suzuki F</u> , Toyota J, Nomura H, Yoshioka K, Seike M, Yotsuyanagi H, Ueno Y.	Guidelines for the treatment of chronic hepatitis and cirrhosis induced by hepatitis C virus infection for the fiscal year 2008 in Japan.	Hepatol Res	40 (1)	8-13	2010

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Akuta N, <u>Suzuki F</u> , Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H.	Amino acid substitutions in the hepatitis C virus core region of genotype 1b affect very early viral dynamics during treatment with telaprevir, peginterferon, and ribavirin.	J Med Virol	82	575-582	2010
Watanabe S, Enomoto N, Koike K, Isumi N, Takikawa H, Hashimoto E, Moriyasu F, Kumada H, Imawari M, PERFECT study group.	Prolonged treatment with pegylated interferon $\alpha$ 2b plus ribavirin improves sustained virological response in chronic hepatitis C genotype 1 patients with late response in a clinical real-life setting in Japan.	Hepatol Res	40	135-144	2010
Akuta N, <u>Suzuki F</u> , Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H	Extending combination therapy with peginterferon plus ribavirin for genotype 2 chronic hepatitis C virological responders: a pilot study of 7 cases.	Intervirol	53	188-192	2010
Arase Y, <u>Suzuki F</u> , Akuta N, Sezaki H, Suzuki Y, Kawamura Y, Kobayashi M, Hosaka T, Yatsuji H, Hirakawa M, Saitoh S, Ikeda K, Kobayashi M, Kumada H.	Efficacy and safety of combination therapy of natural human interferon beta and ribavirin in chronic hepatitis C patients with genotype 1b and high virus load.	Int Med	49	957-963	2010
<u>Suzuki F</u> , Akuta N, Suzuki Y, Yatsuji H, Sezaki H, Arase Y, Hirakawa M, Kawamura Y, Hosaka T, Kobayashi M, Saitoh S, Ikeda K, Kobayashi M, Watahiki S, Kumada H.	The efficacy of switching to entecavir monotherapy in Japanese lamivudine-pretreated patients.	Hepatol Res	25	892-898	2010
Hosaka T, <u>Suzuki F</u> , Kobayashi M, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Akuta N, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H.	HBcrAg is a predictor of post-treatment recurrence of hepatocellular carcinoma during antiviral therapy.	Liv Int	93 (3-4)	109-112	2010

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Kawamura Y, Ikeda K, Hirakawa M, Yatsuji H, Hosaka T, Sezaki H, <u>Suzuki F</u> , Kobayashi M, Kobayashi M, Suzuki Y, Arase Y, Kumada H.	New classification of dynamic computed tomography images predictive of malignant characteristics of hepatocellular carcinoma.	Hepatol Res	40 (10)	1006-1014	2010
Ikeda K, Kobayashi M, Seko Y, Imai N, Hirakawa M, Kawamura Y, Sezaki H, Akuta N, Suzuki Y, <u>Suzuki F</u> , Saitoh S, Arase Y, Kumada H.	Administration of interferon for two or more years decreases early stage hepatocellular carcinoma recurrence rate after radical ablation: A retrospective study of hepatitis C virus-related liver cancer.	Hepatol Res	40 (12)	1168-1175	2010
Kawamura Y, Ikeda K, Hirakawa M, Yatsuji H, Hosaka T, Sezaki H, Kobayashi M, Kobayashi M, Suzuki Y, <u>Suzuki F</u> , Arase Y, Kumada H.	Diabetes enhances hepatocarcinogenesis in noncirrhotic, interferon-treated hepatitis C patients.	Am J Med	123 (10)	951-956	2010
Hashimoto Y, <u>Suzuki F</u> , Hirakawa M, Kawamura Y, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Saitoh S, Suzuki Y, Kobayashi M, Arase Y, Ikeda K, Kumada H.	Clinical and virological effects of long-term (over 5 years) lamivudine therapy.	J Med Virol	82	684-691	2010
Suzuki Y, <u>Suzuki F</u> , Kawamura Y, Yatsuji H, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Miyakawa Y, Kumada H.	Association of HLA-DR14 with Treatment Response in Japanese Patients with Autoimmune Hepatitis.	Dig Dis Sci	55	2070-2076	2010
Hayes CN, Kobayashi M, Akuta N, <u>Suzuki F</u> , Kumada H, Abe H, Miki D, Imamura M, Ochi H, Kamatani N, Nakamura Y, Chayama K.	HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy.	Gut.	60	261-267	2011
Izumi N, Nishiguchi S, Hino K, <u>Suzuki F</u> , Kumada H, Itoh Y, Asahina Y, Tamori A, Hiramatsu N, Hayashi N, Kudo M	Management of hepatitis C: report of the consensus meeting at the 45 <sup>th</sup> annual meeting of the Japan Society of Hepatology (2009).	Hepatol Res	40	347-68	2010

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
<u>Suzuki F</u> , Suzuki Y, Akuta N, Sezaki H, Hirakawa M, Kawamura Y, Hosaka T, Kobayashi M, Saito S, Arase Y, Ikeda K, Kobayashi M, Chayama K, Kamatani N, Miyakawa Y, Kumada H	Influence of ITPA Polymorphisms on Decrease of hemoglobin during treatment with pegylated interferon, ribavirin and telaprevir	Hepatology	53 (2)	416-421	2011
Akuta N, <u>Suzuki F</u> , Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H.	Amino acid substitutions in HCV core region and genetic variation near the interleukin 28B gene effect viral dynamics during telaprevir with peginterferon and ribavirin	Intervirology	DOI: 10.1159/000323526	In	2011
Tadokoro K, <u>Suzuki F</u> , Kobayashi M, Yamaguchi T, Nagano M, Egashira T, Kumada H	Rapid detection of drug-resistant mutations in hepatitis B virus by the PCR-invader assay.	J Virol Method	171	67-73	2011
瀬崎ひとみ, 鈴木文孝, 芥田憲夫, 平川美晴, 川村祐介, 八辻寛美, 保坂哲也, 小林正宏, 鈴木義之, 斎藤聡, 荒瀬康司, 池田健次, 熊田博光	C型慢性肝炎に対するペグインターフェロンとリハビリ併用療法におけるNS3-4Aプロテアーゼ阻害剤(Telaprevir)併用12週間治療のウイルス学的著効の検討	肝臓	51 (7)	394-396	2010
八辻寛美, 鈴木文孝, 平川美晴, 川村祐介, 瀬崎ひとみ, 保坂哲也, 芥田憲夫, 小林正宏, 鈴木義之, 斎藤聡, 荒瀬康司, 池田健次, 岩崎里美, 峰田理恵, 綿引祥予, 小林万利子, 熊田博光	核酸アナログ未使用のB型慢性肝炎症例へのエンテカビル治療中にrtA181Tウイルスが増殖した一症例	肝臓	51 (4)	196-198	2010
小林万利子, 鈴木文孝, 芥田憲夫, 鈴木義之, 瀬崎ひとみ, 八辻寛美, 保坂哲也, 小林正宏, 川村祐介, 平川美晴, 荒瀬康司, 池田健次, 峰田理恵, 岩崎里美, 綿引祥予, 中村祐輔, 茶山一彰, 熊田博光.	IL28BとHCV Core aa70置換との関連	肝臓	51 (6)	322-323	2010
小関至, 木村睦海, 荒川智宏, 中島知明, 桑田靖昭, 赤池淳, 木村卓味, 佐藤隆啓, 狩野吉康, <u>豊田成司</u>	ラミブジンとアデフォビル併用不応例に対するアデフォビルとエンテカビル併用療法	日消誌	108	202-209	2011

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Oze, T., Hiramastu, N., Yakushijin, T., Mochizuki, K., Oshita, M., Hagiwara, H., Mita, E., Ito, T., Fukui, H., Inui, Y., Hijioka, T., Inada, M., Katayama, K., Tamura, S., Yoshihara, H., Inoue, A., Imai, Y., Kato, M., Miyagi, T., Yoshida, Y., Tatsumi, T., Kiso, S., <u>Kanto, T.</u> , Kasahara, A., Takehara, T. and Hayashi, N.	Indications and limitations for aged patients with chronic hepatitis C in pegylated interferon alfa-2b plus ribavirin combination therapy.	J Hepatol			2011 (in press)
Inoue, Y., Hiramatsu, N., Oze, T., Yakushijin, T., Mochizuki, K., Fukuda, K., Mita, E., Haruna, Y., Inoue, A., Imai, Y., Hosui, A., Miyagi, T., Yoshida, Y., Tatsumi, T., Kiso, S., <u>Kanto, T.</u> , Kasahara, A., Takehara, T. and Hayashi, N.	Amino acid substitution in the core protein has no impact on relapse in hepatitis C genotype 1 patients treated with peginterferon and ribavirin.	J Med Virol	83	419-427	2011
Tatsumi T, Takehara T, Miyagi T, Sugiyama T, Aketa H, Sasakawa A, <u>Kanto T</u> , Hiramatsu N, Hayashi N.	$\alpha$ -Galactosylceramide activates antitumor immunity against liver tumor.	Hepatol Res	41	160-169	2010
Tatsumi T, Takehara T, Miyagi T, Nakazuru S, Mita E, <u>Kanto T</u> , Hiramatsu N, Hayashi N.	Hepatitis C virus-specific CD8+ T cell frequencies are associated with the responses of pegylated interferon- $\alpha$ and ribavirin combination therapy in patients with chronic hepatitis C virus infection.	Hepatol Res	41	30-38	2010.
Saito R, Koyano S, Nagai R, Okamura N, <u>Moriya K</u> , Koike K.	Evaluation of a chromogenic agar medium for the detection of extended-spectrum $\beta$ -lactamase-producing Enterobacteriaceae.	Lett Appl Microbiol	51 (6)	704-6	2010
Miyoshi H, <u>Moriya K</u> , Tsutsumi T, Shinzawa S, Fujie H, Shintani Y, Fujinaga H, Goto K, Todoroki T, Suzuki T, Miyamura T, Matsuura Y, Yotsuyanagi H, Koike K.	Pathogenesis of lipid metabolism disorder in hepatitis C: Polyunsaturated fatty acids counteract lipid alterations induced by the core protein.	J Hepatol	22		2010

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Koike K, Tsutsumi T, Yotsuyanagi H, <u>Moriya K.</u>	Lipid metabolism and liver disease in hepatitis C viral infection.	Oncology	8 Supp 11:	24-30.	2010
<u>Moriya K</u> , Miyoshi H, Shinzawa S, Tsutsumi T, Fujie H, Goto K, Shintani Y, Yotsuyanagi H, Koike K.	Hepatitis C virus core protein compromises iron-induced activation of antioxidants in mice and HepG2 cells.	J Med Virol.	82 (5)	776-92.	2010
Koike K, <u>Moriya K</u> , Matsuura Y.	Animal models for hepatitis C and related liver disease.	Hepatol Res	40 (1)	:69-82.	2010
Itakura J, <u>Asahina Y</u> , Tamaki N, Hirayama I, Yasui Y, Tanaka T, Sato M, Ueda K, Kuzuya T, Tsuchiya K, Nakanishi H, Kurosaki M, Gabriel GS, Schneider, Izumi N.	Changes in hepatitis C viral load during first 14 days can predict the undetectable time point of serum viral load by pegylated interferon and ribavirin therapy.	Heptol Res	Inpress		2011
Kurosaki M, Tanaka Y, Nishida N, Sakamoto N, Enomoto N, Honda M, Sugiyama M, Matsuura K, Sugauchi F, <u>Asahina Y</u> , Nakagawa M, Watanabe M, Sakamoto M, Maekawa S, Sakai A, Kaneko S, Ito K, Masaki N, Tokunaga K, Izumi N, Mizokami M.	Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors.	J Hepatol	Inpress		2011
<u>Asahina Y</u> , Tsuchiya K, Tamaki N, Hirayama I, Tanaka T, Sato M, Yasui Y, Hosokawa T, Ueda K, Kuzuya T, Nakanishi H, Itakura J, Takahashi Y, Kurosaki M, Enomoto N, Izumi N.	Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection.	Hepatology	52	518-27	2010
Izumi N, <u>Asahina Y</u> , Kurosaki M.	Predictors of virological response to a combination therapy with pegylated interferon plus ribavirin including virus and host factors.	Hepatitis Reserch and Treatment	2010	703602	2010

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Namiki I, Nishiguchi S, Hino K, Suzuki F, Kumada H, Itoh Y, <u>Asahina Y</u> , Tamori A, Hiramatsu N, Hayashi N, Kudo M.	Management of hepatitis C; Report of the Consensus Meeting at the 45th Annual Meeting of the Japan Society of Hepatology (2009).	Hepatol Res	40	347-68	2010
Kurosaki M, Matsunaga K, Hirayama I, Tanaka T, Sato M, Yasui Y, Tamaki N, Hosokawa T, Ueda K, Tsuchiya K, Nakanishi H, Ikeda H, Itakura J, Takahashi Y, <u>Asahina Y</u> , Higaki M, Enomoto N, Izumi N.	A predictive model of response to peginterferon ribavirin in chronic hepatitis C using classification and regression tree analysis.	Hepatol Res	40	251-60	2010
Kurosaki M, Hosokawa T, Matsunaga K, Hirayama I, Tanaka T, Sato M, Yasui Y, Tamaki N, Ueda K, Tsuchiya K, Kuzuya T, Nakanishi H, Itakura J, Takahashi Y, <u>Asahina Y</u> , Enomoto N, Izumi N.	Hepatic steatosis in chronic hepatitis C is a significant risk factor for developing hepatocellular carcinoma independent of age, sex, obesity, fibrosis stage and response to interferon therapy.	Hepatol Res	40	870-7	2010
Kadokura M, Maekawa S, Sueki R, Miura M, Komase K, Shindo H, Amemiya F, Uetake T, Inoue T, <u>Sakamoto M</u> , Nakagawa M, Sakamoto N, Watanabe M, Enomoto N.	Analysis of the Complete Open Reading Frame of Hepatitis C Virus Genotype 2a Infection Reveals Critical Site Influencing the Response to Peginterferon and Ribavirin Therapy.	Hepatol Int	in press		2011
Kurosaki M, Sakamoto N, Iwasaki M, <u>Sakamoto M</u> , Suzuki Y, Hiramatsu N, Sugauchi F, Tamori A, Nakagawa M, Izumi N.	Sequences in the Interferin Sensitivity Determining Region and Core Region of Hepatitis C Virus Impact Pretreatment Prediction of Response to Peg-interferon Plus Ribavirin: Data Mining Analysis.	J Med Virol	83	445-452	2011



発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Kurosaki M, Tanaka Y, Nishida N, Sakamoto N, Enomoto N, Honda M, Sugauchi M, Matsuura K, Sugauchi F, Asahina Y, Nakagawa M, Watanabe M, <u>Sakamoto M</u> , Maekawa S, Sakai A, Kaneko S, Ito K, Masaki N, Tokunaga K, Izumi N, Mizokami M.	Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in <i>IL28B</i> and viral factors.	J Hepatol	54	439-448	2011
Kurosaki M, Sakamoto N, Iwasaki M, <u>Sakamoto M</u> , Suzuki Y, Hiramatsu N, Sugauchi F, Yatsuhashi H, Izumi N.	Pretreatment prediction of response to peginterferon plus ribavirin therapy in genotype 1 chronic hepatitis C using detemining analysis.	J Gastroenterol	in press (published online September 2010)		2010
Honda M, <u>Sakai A</u> , Yamashita T, Nakamoto Y, Mizukoshi E, Sakai Y, Yamashita T, Nakamura M, Shirasaki T, Horimoto K, Tanaka Y, Tokunaga K, Mizokami M, Kaneko S; Hokuriku Liver Study Group	Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C	Gastroenterology	139	499-509	2010
Nagatsu A, <u>Taniguchi M</u> , Shimamura T, Suzuki T, Yamashita K, Kawakami h, Abo D, Kamiyama T, Furukawa F, Todo S	Endoscopic naso-pancreatic drainage for the treatment of pancreatic fistula occurring after living donor liver transplantation.	World Journal of Gastroenterology	in press		2011
Uchida K, <u>Taniguchi M</u> , Shimamura T, Suzuki T, Yamashita K, Ota M, Kamiyama T, Matsushita M, Furukawa H, Todo S	Three-Dimensional computed tomography scan analysis of hepatic vasculatures in the donor liver for living donor liver transplantation.	Liver Transplantation	16 (9)	1062-8	2010
Yoneda S, <u>Umemura T</u> , Katsuyama Y, Kamiyo A, Joshita S, Komatsu M, Ichijo T, Matsumoto A, Yoshizawa K, Ota M, Tanaka E.	Association of serum cytokine levels with treatment response to pegylated interferon and ribavirin therapy in genotype 1 chronic hepatitis C patients	J Infect Dis	in press		2011
<u>Umemura T</u> , Zen Y, Nakanuma Y, Kiyosawa K.	Another cause of autoimmune hepatitis.	Hepatology	52	389-390	2010

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Joshita S, <u>Umemura T</u> , Yoshizawa K, Katsuyama Y, Tanaka E, Nakamura M, Ishibashi H, Ota M, the Shinshu PBC Study Group.	Association analysis of cytotoxic T-lymphocyte antigen 4 gene polymorphisms with primary biliary cirrhosis in Japanese patients.	J Hepatol	53	537-541	2010
Abe H, <u>Imamura M</u> , Hiraga N, Tsuge M, Mitsui F, Kawaoka T, Takahashi S, Ochi H, Maekawa T, Hayes CN, Tateno C, Yoshizato K, Murakami S, Yamashita N, Matsuhira T, Asai K, Chayama K	ME3738 enhances the effect of interferon and inhibits hepatitis C virus replication both in vitro and in vivo.	J Hepatol	in press		2011
Ohara E, Hiraga N, <u>Imamura M</u> , Iwao E, Kamiya N, Yamada I, Kono T, Onishi M, Hirata D, Mitsui F, Kawaoka T, Tsuge M, Takahashi S, Abe H, Hayes CN, Ochi H, Tateno C, Yoshizato K, Tanaka S, Chayama K	Elimination of Hepatitis C Virus by Short Term NS3-4A and NS5B Inhibitor Combination Therapy in Human Hepatocyte Chimeric Mice.	J Hepatol	in press		2011
Chayama K, Hayes CN, Hiraga N, Abe H, Tsuge M, <u>Imamura M</u> .	Animal model for study of human hepatitis viruses.	J Gastrl Hepatol	26 (1)	13-18	2011
Suda G, Sakamoto N, Itsui Y, Nakagawa M, Tasaka-Fujita M, Funaoka Y, Watanabe T, Nitta S, Kiyohashi K, Azuma S, Kakinuma S, Tsuchiya K, <u>Imamura M</u> , Hiraga N, Chayama K, Watanabe M	IL-6-mediated intersubgenotypic variation of interferon sensitivity in hepatitis C virus genotype 2a/2b chimeric clones.	Virology	407 (1)	80-90	2010
Mishima K, Sakamoto N, Sekine-Osajima Y, Nakagawa M, Itsui Y, Azuma S, Kakinuma S, Kiyohashi K, Kitazume A, Tsuchiya K, <u>Imamura M</u> , Hiraga N, Chayama K, Wakita T, Watanabe M.	Cell culture and in vivo analyses of cytopathic hepatitis C virus mutants.	Virology	405 (2)	361-9	2010
Kamiya N, Iwao E, Hiraga N, Tsuge M, <u>Imamura M</u> , Takahashi S, Miyoshi S, Tateno C, Yoshizato K, Chayama K	Practical Evaluation of a Mouse with Chimeric Human Liver Model for Hepatitis C Virus Infection Using an NS3-4A Protease Inhibitor	J Gen Virol	91 (Pt7)	1668-77	2010

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, <u>Sezaki H</u> , Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H.	Amino acid substitutions in the hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to Telaprevir with peginterferon and ribavirin	Hepatology	52 (2)	421-429	2010
Kobayashi M, Akuta N, Suzuki F, Hosaka T, <u>Sezaki H</u> , Kobayashi M, Suzuki Y, Arase Y, Ikeda K, Watahiki S, Mineta R, Iwasaki S, Miyakawa Y, Kumada H.	Influence of amino-acid polymorphism in the core protein on progression of liver disease in patients infected with hepatitis C virus genotype 1b.	J Med Virol	82	41-48	2010
Suzuki F, Suzuki Y, Akuta N, <u>Sezaki H</u> , Yatsuji H, Arase Y, Hirakawa M, Kawamura Y, Hosaka T, Kobayashi M, Saitoh S, Ikeda K, Kobayashi M, Watahiki S, Mineta R, Iwasaki S, Kumada H.	Sustained virological response in a patient with chronic hepatitis C treated by monotherapy with the NS3-4A protease inhibitor telaprevir.	J cln virol	47 (1)	76-78	2010
Arase Y, Suzuki F, Suzuki Y, Akuta N, Kobayashi M, <u>Sezaki H</u> , Hosaka T, Kawamura Y, Yatsuji H, Hirakawa M, Ikeda K, Kobayashi M, Kumada H.	Virus clearance reduces bone fracture in postmenopausal women with osteoporosis and chronic liver disease caused by hepatitis C virus.	J Med Virol	82	390-395	2010
Kobayashi M, Suzuki F, Akuta N, Yatsuji H, Hosaka T, <u>Sezaki H</u> , Kobayashi M, Kobayashi M, Kawamura Y, Suzuki Y, Arase Y, Ikeda K, Mineta R, Iwasaki S, Watahiki S, Kumada H.	Correlation of YMDD mutation and breakthrough hepatitis with hepatitis B virus DNA and serum ALT during lamivudine treatment.	Hepatol Res	40 (2)	125-134	2010
Hosaka T, Suzuki F, Kobayashi M, Hirakawa M, Kawamura Y, Yatsuji H, <u>Sezaki H</u> , Akuta N, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Miyakawa Y, Kumada H.	Development of HCC in patients receiving adefovir dipivoxil for lamivudine-resistant hepatitis B virus mutants.	Hepatol Res	40 (2)	145-152	2010

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, <u>Sezaki H</u> , Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H.	Amino acid substitutions in the hepatitis C virus core region of genotype 1b affect very early viral dynamics during treatment with telaprevir, peginterferon, and ribavirin.	J Med Virol	82	575-582	2010
Watanabe S, Enomoto N, Koike K, Isumi N, Takikawa H, Hashimoto E, Moriyasu F, Kumada H, Imawari M, PERFECT study group.	Prolonged treatment with pegylated interferon $\alpha$ 2b plus ribavirin improves sustained virological response in chronic hepatitis C genotype 1 patients with late response in a clinical real-life setting in Japan.	Hepatol Res	40	135-144	2010
Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, <u>Sezaki H</u> , Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H	Extending combination therapy with peginterferon plus ribavirin for genotype 2 chronic hepatitis C virological responders: a pilot study of 7 cases.	Intervirol	53	188-192	2010
Arase Y, Suzuki F, Akuta N, <u>Sezaki H</u> , Suzuki Y, Kawamura Y, Kobayashi M, Hosaka T, Yatsuji H, Hirakawa M, Saitoh S, Ikeda K, Kobayashi M, Kumada H.	Efficacy and safety of combination therapy of natural human interferon beta and ribavirin in chronic hepatitis C patients with genotype 1b and high virus load.	Int Med	49	957-963	2010
Suzuki F, Akuta N, Suzuki Y, Yatsuji H, <u>Sezaki H</u> , Arase Y, Hirakawa M, Kawamura Y, Hosaka T, Kobayashi M, Saitoh S, Ikeda K, Kobayashi M, Watahiki S, Kumada H.	The efficacy of switching to entecavir monotherapy in Japanese lamivudine-pretreated patients.	Hepatol Res	25	892-898	2010
Hosaka T, Suzuki F, Kobayashi M, Hirakawa M, Kawamura Y, Yatsuji H, <u>Sezaki H</u> , Akuta N, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H.	HBcrAg is a predictor of post-treatment recurrence of hepatocellular carcinoma during antiviral therapy.	Liv Int	93 (3-4)	109-112	2010